Concepts (132)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Meningococcal Infections | 2 | 2023 | 77 | 0.940 |
Why?
|
Meningococcal Vaccines | 2 | 2023 | 95 | 0.920 |
Why?
|
Vaccines | 4 | 2022 | 822 | 0.770 |
Why?
|
Neisseria meningitidis, Serogroup A | 1 | 2020 | 6 | 0.750 |
Why?
|
Antibodies, Viral | 11 | 2023 | 3176 | 0.680 |
Why?
|
Human Experimentation | 1 | 2019 | 127 | 0.640 |
Why?
|
Orthomyxoviridae | 1 | 2019 | 156 | 0.610 |
Why?
|
Viruses | 1 | 2021 | 374 | 0.590 |
Why?
|
Influenza, Human | 4 | 2022 | 1479 | 0.580 |
Why?
|
Hematopoietic Stem Cell Transplantation | 3 | 2023 | 5442 | 0.550 |
Why?
|
Systems Biology | 1 | 2019 | 469 | 0.520 |
Why?
|
Influenza Vaccines | 4 | 2022 | 738 | 0.450 |
Why?
|
Host-Pathogen Interactions | 1 | 2019 | 1477 | 0.360 |
Why?
|
Hepatitis C, Chronic | 2 | 2015 | 1031 | 0.360 |
Why?
|
Hepatitis B virus | 1 | 2013 | 513 | 0.340 |
Why?
|
Pandemics | 5 | 2022 | 8388 | 0.330 |
Why?
|
Hepatitis B, Chronic | 1 | 2013 | 393 | 0.320 |
Why?
|
Adenine | 1 | 2013 | 936 | 0.300 |
Why?
|
Antibodies, Neutralizing | 5 | 2022 | 1978 | 0.280 |
Why?
|
Antiviral Agents | 3 | 2014 | 2987 | 0.280 |
Why?
|
Vaccines, Synthetic | 3 | 2022 | 634 | 0.260 |
Why?
|
Immunoglobulin G | 5 | 2023 | 4560 | 0.260 |
Why?
|
Aluminum Hydroxide | 1 | 2022 | 58 | 0.210 |
Why?
|
Immune Evasion | 2 | 2022 | 360 | 0.200 |
Why?
|
Vaccination | 3 | 2023 | 3278 | 0.190 |
Why?
|
Lymphopenia | 1 | 2023 | 285 | 0.190 |
Why?
|
Toxoplasmosis | 1 | 2021 | 91 | 0.190 |
Why?
|
Antibody Formation | 2 | 2022 | 1402 | 0.180 |
Why?
|
Toxoplasma | 1 | 2021 | 150 | 0.180 |
Why?
|
Health Priorities | 1 | 2021 | 380 | 0.160 |
Why?
|
Africa South of the Sahara | 1 | 2020 | 724 | 0.150 |
Why?
|
Humans | 34 | 2023 | 744343 | 0.140 |
Why?
|
Klebsiella Infections | 1 | 2018 | 138 | 0.140 |
Why?
|
Viral Vaccines | 1 | 2022 | 636 | 0.140 |
Why?
|
Saliva | 1 | 2020 | 809 | 0.140 |
Why?
|
Klebsiella pneumoniae | 1 | 2018 | 251 | 0.140 |
Why?
|
Hepacivirus | 2 | 2014 | 1379 | 0.130 |
Why?
|
Seasons | 1 | 2021 | 1493 | 0.130 |
Why?
|
Immunoglobulin A | 3 | 2023 | 992 | 0.120 |
Why?
|
Sjogren's Syndrome | 1 | 2015 | 233 | 0.120 |
Why?
|
Drug Resistance, Multiple, Bacterial | 1 | 2018 | 567 | 0.110 |
Why?
|
Hematologic Diseases | 1 | 2015 | 498 | 0.100 |
Why?
|
Drug Discovery | 1 | 2019 | 1058 | 0.100 |
Why?
|
Disease Outbreaks | 1 | 2020 | 1772 | 0.090 |
Why?
|
Sensitivity and Specificity | 2 | 2023 | 14722 | 0.090 |
Why?
|
Cross Reactions | 2 | 2022 | 841 | 0.090 |
Why?
|
Viremia | 1 | 2013 | 736 | 0.090 |
Why?
|
Metabolic Diseases | 1 | 2015 | 658 | 0.080 |
Why?
|
Interferon-alpha | 1 | 2012 | 895 | 0.080 |
Why?
|
Interleukins | 1 | 2012 | 791 | 0.080 |
Why?
|
Lymphangioleiomyomatosis | 1 | 2009 | 210 | 0.080 |
Why?
|
HIV Infections | 2 | 2014 | 16718 | 0.080 |
Why?
|
Immunoglobulin M | 2 | 2023 | 1537 | 0.070 |
Why?
|
Skin Diseases | 1 | 2015 | 1065 | 0.070 |
Why?
|
Attitude | 2 | 2022 | 776 | 0.070 |
Why?
|
Immunity, Cellular | 1 | 2013 | 1607 | 0.070 |
Why?
|
Lymphoma | 1 | 2015 | 1877 | 0.070 |
Why?
|
Hepatocytes | 1 | 2012 | 1211 | 0.060 |
Why?
|
Rare Diseases | 1 | 2009 | 553 | 0.060 |
Why?
|
Kidney Diseases | 1 | 2015 | 2149 | 0.060 |
Why?
|
United States Food and Drug Administration | 2 | 2022 | 1584 | 0.060 |
Why?
|
Viral Load | 1 | 2013 | 3299 | 0.060 |
Why?
|
Autoimmune Diseases | 1 | 2015 | 2133 | 0.060 |
Why?
|
Hemagglutination Inhibition Tests | 1 | 2022 | 77 | 0.060 |
Why?
|
Squalene | 1 | 2022 | 32 | 0.060 |
Why?
|
Polysorbates | 1 | 2022 | 41 | 0.050 |
Why?
|
Coronavirus Infections | 1 | 2020 | 3133 | 0.050 |
Why?
|
Pneumonia, Viral | 1 | 2020 | 3240 | 0.050 |
Why?
|
Vaccines, Conjugate | 1 | 2023 | 333 | 0.050 |
Why?
|
Middle Aged | 6 | 2023 | 213383 | 0.050 |
Why?
|
United States | 4 | 2022 | 69872 | 0.050 |
Why?
|
Public-Private Sector Partnerships | 1 | 2021 | 121 | 0.050 |
Why?
|
Patient Participation | 1 | 2009 | 1457 | 0.050 |
Why?
|
Anti-Bacterial Agents | 1 | 2018 | 7181 | 0.040 |
Why?
|
Lung Diseases | 1 | 2009 | 1886 | 0.040 |
Why?
|
Immunization, Secondary | 1 | 2021 | 340 | 0.040 |
Why?
|
CD8-Positive T-Lymphocytes | 1 | 2013 | 4479 | 0.040 |
Why?
|
T-Lymphocytes, Regulatory | 1 | 2013 | 2988 | 0.040 |
Why?
|
Double-Blind Method | 1 | 2013 | 12026 | 0.040 |
Why?
|
Cryoelectron Microscopy | 1 | 2022 | 571 | 0.040 |
Why?
|
Health Personnel | 2 | 2022 | 3218 | 0.040 |
Why?
|
Influenza A virus | 1 | 2021 | 456 | 0.040 |
Why?
|
Male | 6 | 2023 | 350118 | 0.040 |
Why?
|
Antibodies, Bacterial | 1 | 2023 | 1470 | 0.040 |
Why?
|
Adjuvants, Immunologic | 1 | 2022 | 1000 | 0.040 |
Why?
|
Retrospective Studies | 2 | 2023 | 77449 | 0.040 |
Why?
|
Crystallography, X-Ray | 1 | 2022 | 2011 | 0.040 |
Why?
|
Immunization | 1 | 2021 | 1256 | 0.040 |
Why?
|
Water | 1 | 2022 | 1395 | 0.030 |
Why?
|
RNA, Messenger | 2 | 2021 | 13033 | 0.030 |
Why?
|
Aged | 3 | 2023 | 163280 | 0.030 |
Why?
|
Postoperative Complications | 1 | 2018 | 15295 | 0.030 |
Why?
|
HIV-1 | 1 | 2013 | 6939 | 0.030 |
Why?
|
Epitopes | 1 | 2022 | 2571 | 0.030 |
Why?
|
Clinical Laboratory Techniques | 1 | 2020 | 738 | 0.030 |
Why?
|
Polysaccharides | 1 | 2022 | 1053 | 0.030 |
Why?
|
Prospective Studies | 2 | 2023 | 53288 | 0.030 |
Why?
|
Clinical Trials as Topic | 1 | 2009 | 7913 | 0.030 |
Why?
|
Life Cycle Stages | 1 | 2014 | 160 | 0.030 |
Why?
|
Physician's Role | 1 | 2020 | 943 | 0.030 |
Why?
|
Craniotomy | 1 | 2018 | 729 | 0.030 |
Why?
|
Delivery of Health Care | 2 | 2022 | 5319 | 0.030 |
Why?
|
Evolution, Molecular | 1 | 2022 | 1940 | 0.030 |
Why?
|
Fatal Outcome | 1 | 2018 | 1850 | 0.030 |
Why?
|
Female | 5 | 2023 | 380194 | 0.030 |
Why?
|
Neoplasms | 1 | 2021 | 21683 | 0.030 |
Why?
|
Models, Molecular | 1 | 2022 | 5456 | 0.020 |
Why?
|
Adult | 4 | 2022 | 214055 | 0.020 |
Why?
|
Academic Medical Centers | 1 | 2021 | 2759 | 0.020 |
Why?
|
Risk Factors | 3 | 2022 | 72290 | 0.020 |
Why?
|
Protein Binding | 1 | 2022 | 9386 | 0.020 |
Why?
|
Interferons | 1 | 2012 | 706 | 0.020 |
Why?
|
Respiration, Artificial | 1 | 2018 | 2569 | 0.020 |
Why?
|
North America | 1 | 2009 | 1249 | 0.020 |
Why?
|
Diagnosis, Differential | 1 | 2020 | 12959 | 0.020 |
Why?
|
Liver Cirrhosis | 1 | 2014 | 1863 | 0.010 |
Why?
|
Drug Therapy, Combination | 1 | 2014 | 6489 | 0.010 |
Why?
|
Child | 2 | 2022 | 77709 | 0.010 |
Why?
|
Cross-Sectional Studies | 1 | 2021 | 25043 | 0.010 |
Why?
|
Genotype | 1 | 2014 | 12951 | 0.010 |
Why?
|
Time Factors | 1 | 2021 | 40075 | 0.010 |
Why?
|
Cell Line | 1 | 2012 | 15997 | 0.010 |
Why?
|
Patient Selection | 1 | 2009 | 4215 | 0.010 |
Why?
|
Prevalence | 1 | 2014 | 15226 | 0.010 |
Why?
|
Mutation | 1 | 2022 | 29786 | 0.010 |
Why?
|
Young Adult | 1 | 2021 | 56430 | 0.010 |
Why?
|
Mice | 1 | 2022 | 81183 | 0.010 |
Why?
|
Research Design | 1 | 2009 | 5987 | 0.010 |
Why?
|
Adolescent | 1 | 2021 | 85781 | 0.010 |
Why?
|
Age Factors | 1 | 2009 | 18370 | 0.010 |
Why?
|
Health Services Accessibility | 1 | 2009 | 5137 | 0.010 |
Why?
|
Animals | 1 | 2022 | 168757 | 0.010 |
Why?
|
Concepts
(132)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(71)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People in same department with this person.
Explore
_